Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

38 results about "Leukemia lymphoma" patented technology

Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol

The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

Antibody composition for leukemia/lymphoma immunotyping preliminary screening and application thereof

ActiveCN113777327ATo achieve the purpose of confirming the diagnosisHigh precisionIndividual particle analysisBiological testingAntigenDisease
The invention provides a reagent composition for leukemia / lymphoma typing. The reagent composition comprises 19 kinds of antibodies. According to the optimized antibody combination, the fluorescence labeling combination of the corresponding antibody and the result interpretation method, the AML, the ALL-B, the ALL-T, the MPAL, the NHL-B, the NHL-T, the PCN, the NHL-NK and the chronic myeloid tumors can be preliminarily screened comprehensively and efficiently only by using 19 antibodies and one-tube cell one-time sample loading, and the aim of clearly diagnosing the AML, the ALL-B, the ALL-T, the MPAL, the NHL-B, the NHL-T and the PCN is achieved. The 19 antibody combinations are used for analyzing the expression of tumor cell antigens in a sample, and leukemia-related immunophenotypes (LAIP) which can be used for monitoring post-treatment trace residual disease (MRD) in the antibody combinations are determined.
Owner:PEOPLES HOSPITAL PEKING UNIV

Antibody composition and application of antibody composition in leukemia and lymphoma typing

ActiveCN105606797AOptimizing Fluorescent Labeling CombinationsSimple methodMaterial analysisTypingCD33
The invention belongs to the technical field of antibody medicines and provides two types of antibody compositions including CD45 antibody, CD13 antibody, CD33 antibody and CD7 antibody or including CD45 antibody, CD117 antibody, CD34 antibody and CD19 antibody. The invention further provides a leukemia and lymphoma typing kit comprising the two types of antibody compositions and capable of being used with a flow cytometry to achieve typing of various hematological neoplasms.
Owner:ZHEJIANG BOZHEN BIOTECH CO LTD

Application of macrolide compound in reversing tumor multidrug resistance and enhancing anti-tumor curative effect

The invention relates to an application of a macrolide compound in reversing tumor multidrug resistance and enhancing an anti-tumor curative effect. The compound has the functions of inhibiting ABC transport protein activity, improving the concentration of a substrate chemotherapeutic drug of the ABC transport protein in tumor cells, reversing tumor multidrug resistance, and enhancing curative effects of the ABC transport protein substrate chemotherapeutic drugs such as antibiotic tumor chemotherapeutic drugs, plant-derived tumor chemotherapeutic drugs and small-molecular tyrosine kinase inhibitors, and has an effect of enhancing curative effects when being combined with antitumor drugs. Effective dose of the compound is combined with effective dose of an anti-tumor drug for application, apharmaceutically acceptable compound preparation is prepared by mixing with an effective dose of the antitumor drug, and is used for treating tumors including leukemia, lymphoma, gastric cancer, colon cancer, liver cancer, pancreatic cancer, breast cancer, nasopharyngeal carcinoma, cervical carcinoma, melanoma, multiple myeloma, and sarcoma.
Owner:FUJIAN MEDICAL UNIV

Ten-color antibody composition and application thereof in leukemia-lymphomas subtype

The invention belongs to the technical field of antibodies, and provides an antibody composition composed of ten antibodies, wherein the tan antibodies comprises CD71 resistant antibody, CD7 resistant antibody, CD13 resistant antibody, CD33 resistant antibody, CD19 resistant antibody, CD117 resistant antibody, CD34 resistant antibody, CD10 resistant antibody, HLA-DR resistant antibody, and CD45 resistant antibody. The invention provides a leukemia-lymphomas primary screening kit containing the antibodies, and the application thereof.
Owner:ZHEJIANG BOZHEN BIOTECH CO LTD

Novel application of scutellarein

The invention discloses application of scutellarein in preparing angiogenesis treatment medicines, and belongs to the field of pharmacy. Experimental study proves that the scutellarein has higher angiogenesis inhibition function, and has exact prevention and treatment functions on angiogenesis-related diseases such as tumor, leukemia, lymphoma and hemangioma angiogenesis, benign angiogenesis, arthritis diseased tissue angiogenesis, eye diseased tissue angiogenesis and the like, and meanwhile, the scutellarein also has remarkable inhibition on stigmatization during wound healing. The scutellarein can directly act on endothelial cells of vessels, has small administration dosage and high clinical effect during clinical application, side effects are small, and drug resistance is not generated easily.
Owner:CHENGDU UNIV OF TRADITIONAL CHINESE MEDICINE

Chimeric antigen receptor and application thereof

The invention provides a chimeric antigen receptor. The chimeric antigen receptor comprises an extracellular structural domain, a transmembrane structural domain and an intracellular structural domainwhich are connected in sequence, wherein the extracellular structural domain comprises an antigen recognition region and a hinge region; and one end of the intracellular structural domain, which is connected with the transmembrane structural domain, is connected with a CD3 epsilon intracellular region. The chimeric antigen receptor provided by the invention can further improve the treatment effect of B-cell leukemia lymphoma in B-cell leukemia lymphoma treatment, and reduces inflammatory cytokines generated by macrophage monocyte activation by down-regulating cytokines of the chimeric antigenreceptor, so that cytokine storm can be prevented at an early stage, and the risk of neurotoxicity can be reduced. The treatment effect of solid tumors with high mesothelin expression is further improved in mesothelin positive tumor treatment, and meanwhile, cytokine storm can be prevented in an early stage and the risk of neurotoxicity can be reduced.
Owner:CENT FOR EXCELLENCE IN MOLECULAR CELL SCI CHINESE ACAD OF SCI

Mannan-binding lectin (MBL) in the treatment of immunocompromised conditions asssociated with cancer

The present invention pertains to the use of subunits and oligomers of mannan- binding lectin (MBL) in prophylactic and / or curative treatment of an immunocompromised individual such as subjects suffering from solid tumors or haematological cancers. Solid tumors include such as female cancers, male cancers, cancers of the respiratory system, cancers of the gastro intestinal system, the renal system and further subjects suffering from thyroid cancer and melanomas. Haematological cancers include leukaemia, lymphoma and myeloma. The immunocompromised condition of the individual may be due to a cancer disease as mentioned herein or the treatment of said cancer disease.
Owner:内蒂穆恩公司

Application of ethanone compound in preparation of medicine for treating tumors

The invention discloses an application of 1-(5-(3-((4-chlorobenzyl) amino)-2-hydroxypropoxy)-2-methyl-1-(p-tolyl)-1H-indole-3-yl) ethanone or pharmaceutically acceptable salt thereof in preparation ofa medicine for treating or preventing tumor diseases. The product is used for relieving and / or adjunctively treating and / or treating myeloma, leukemia, lymphoma, pancreatic cancer, gastric cancer, breast cancer, ovarian cancer, lung cancer, liver cancer, skin cancer, rectal cancer, prostate cancer, thyroid cancer and other tumors. The 1-(5-(3-((4-chlorobenzyl) amino)-2-hydroxypropoxy)-2-methyl-1-(p-tolyl)-1 hydrogen-indole-3-yl) ethanone has a remarkable specific inhibition effect on PI3K gamma (polyisocyanurate).
Owner:JIANGNAN UNIV

Application of small molecule compound in preparation of human La protein inhibitor

PendingCN114668759AActs as an inhibitorInhibit biological functionOrganic active ingredientsDigestive systemDiseaseCancer research
The invention belongs to the technical field of pharmacy, and relates to an application of small molecule compounds ZINC5921027 and ZINC1413516 in preparation of human La protein inhibitors, in particular to an application in preparation of drugs for preventing, delaying or treating high-expression human La protein participated or mediated diseases. The small molecule compound can be effectively combined with human La protein, inhibits the most basic biological function of the La protein, and plays a role of a human La protein inhibitor. The prepared human La protein inhibitor is suitable for treating malignant tumors participated or mediated by a high La protein expression pathway and diseases secondary to increase of virus replication participated or mediated by the high La protein expression pathway. The malignant tumors comprise ovarian cancer, cervical cancer, endometrial cancer, breast cancer, liver cancer, head and neck lymphocyte cancer, oral lymphocyte cancer, leukemia, lymphoma and the like. Diseases secondary to the increased virus replication include hepatitis B, hepatitis C and herpes simplex.
Owner:THE OBSTETRICS & GYNECOLOGY HOSPITAL OF FUDAN UNIV

Method to diagnose a cmmrd

PendingUS20220136066A1Simplify and improve diagnosisMicrobiological testing/measurementSequence analysisLeukemia lymphoma
The present invention relates to the diagnostic of CMMRD. In the present work, the inventors aimed to develop a test that could drastically simplify and improve the diagnosis of CMMRD based on DNA sequence analysis of primary blood cells (PBCs) from patients. Using massive parallel sequencing, they explored the possibility that MSI, the main genomic and functional consequence of constitutive MMR-deficiency, was likely to occur in CMMRD PBCs well before any transformation. Thus the present invention relates to a method of diagnosing a CMMRD cancer or a MSI leukemia / lymphoma in a patient in need thereof.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2

Human antibodies, pharmaceutical compositions and methods

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to Globo H, stage-specific embryonic antigen 3 (SSEA-3) and stage-specific embryonic antigen 4 (SSEA-4)are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cellsurfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.
Owner:OBI PHARMA

Combination therapy for treatment of hematological diseases

The present application relates to treatment of a hematological disease selected from leukemia, lymphoma, and multiple myeloma in a patient in need thereof, comprising administering to the patient: (a) a therapeutically effective amount of a selective JAK1 inhibitor; (b) a therapeutically effective amount of an immunomodulatory agent, and (c) a therapeutically effective amount of a steroid.
Owner:INCYTE CORP

Automatic cerebrospinal fluid cell analysis system based on artificial intelligence

The invention discloses an automatic cerebrospinal fluid cell analysis system based on artificial intelligence. The system comprises an establishment method of a cerebrospinal fluid cell image featurelibrary, a cerebrospinal fluid cell image feature acquisition method and device, and an automatic cerebrospinal fluid cell image identification and counting method. The invention overcomes the defects in the prior art, and provides a cerebrospinal fluid cell image library establishment method, a cerebrospinal fluid cell image acquisition method and device, and a cerebrospinal fluid cell image automatic identification and counting method. Feature extraction is automatically carried out on a cerebrospinal fluid cell image, pixel-level segmentation is carried out on cerebrospinal fluid cells, the segmented cerebrospinal fluid cells are classified, and cells of the whole cerebrospinal fluid cell image are counted. According to the invention, the working efficiency of brain cell detection is greatly improved, the labor intensity of workers is reduced, and an important cerebrospinal fluid cell detection means is provided for the diagnosis of diseases such as central nervous system infection, meningeal leukemia, lymphoma, cerebral parasitic diseases, cerebrovascular diseases, immune degeneration and the like.
Owner:GENERAL HOSPITAL OF NINGXIA MEDICAL UNIV +2

Selective Anti-cancer agent effective for prevention and treatment

ActiveUS20210015803A1Minimizes any systemic toxicityReduce morbidityOrganic active ingredientsAntipyreticAnticarcinogenMelanoma
De-ethylflavopereirine, a pharmaceutically acceptable salt thereof, a solvate or a hydrate thereof, or a pharmaceutically acceptable salt of a solvate or a hydrate thereof may be used as cancer therapy (i.e., prevention and / or treatment) in a subject in need thereof, including a pathological condition such as inflammation, especially chronic, or cancer (e.g., a carcinoma, a sarcoma, a melanoma, a leukemia, a lymphoma), especially a solid tumor and / or a metastasis thereof. In particular, systemic administration of such improved anti-cancer agents in effective amounts may selectively destroy cancer cells (including cancer stem cells) in a solid tumor and / or at a site of metastasis. They are well-tolerated by the subject, even at large systemic doses and their resulting high concentrations in the circulation, and provide safe and effective anti-cancer agents.
Owner:MOLECULAR INT RES

Application of a macrolide compound in reversing tumor multidrug resistance and enhancing antitumor efficacy

The invention relates to the application of a macrocyclic lactone compound in reversing multi-drug resistance of tumors and enhancing anti-tumor curative effect. The compound can inhibit the activity of ABC transporter and increase the concentration of chemotherapeutic drugs which are substrates of ABC transporter in tumor cells. Reverse tumor multidrug resistance, enhance the curative effect of antibiotic tumor chemotherapeutic drugs, plant-derived tumor chemotherapeutic drugs and small molecule tyrosine kinase inhibitors and other ABC transporter substrate chemotherapeutic drugs, and combine with anti-tumor drugs to enhance the curative effect effect. The effective dose of the compound is used in combination with an effective dose of an antineoplastic drug, including being mixed with an effective dose of an antineoplastic drug to prepare a pharmaceutically acceptable compound preparation, which is used for leukemia, lymphoma, gastric cancer, colon cancer, liver cancer, pancreatic cancer, etc. Cancer, breast cancer, nasopharyngeal cancer, cervical cancer, melanoma, multiple myeloma, sarcoma, including tumor treatment.
Owner:FUJIAN MEDICAL UNIV

Human derived bradeion proteins, DNA coding for the proteins, and uses thereof

This invention relates to a human-derived bradeion protein having the following properties:[0001](i) it is a transmembranous protein;[0002](ii) it has a transmembranous portion, an extracellular portion, and a cytoplasmic portion in its molecule as determined by a hydrophobicity analysis according to Kyte-Doolittle method;[0003](iii) it is expressed in the human adult normal brain and heart, the expression level thereof in the heart being about 10% or lower of that in the brain, while it is not expressed in other adult normal organs of spleen, lung, liver, skeletal muscle, kidney and pancreas, and in fetal brain, lung, heart and kidney;[0004](iv) it induces programmed cell death when over-expressed in a cultured human brain-derived undifferentiated nerve cell line;[0005](v) it induces termination of cell division and aging when over-expressed in a cultured human brain-derived differentiated nerve cell;[0006](vi) it is located in cytoplasm in the course of the induced cell death, and forms an intracellular aggregate when overexpressed; and[0007](vii) it is expressed in a human colorectal cancer cell line or in a human malignant melanoma cell line, but not in leukemia, lymphoma and lung carcinoma,to a DNA encoding said bradeion protein, to a vector comprising said DNA, to a host cell comprising said vector, and to a method for detecting a cancer such as colorectal cancer or malignant melanoma.
Owner:NAT INST OF ADVANCED IND SCI & TECH

Methods and Compositions For Predicting Chronic Lung Allograft Dysfunction

The present invention relates to a method for predicting the risk of having the CLAD in a subject by measuring the expression level of TCL1A in a biological sample obtained from said subject. Inventors have used a large-scale gene expression profiling of whole blood cells to identify early biomarkers of BOS. Microarray experiments performed from 80 patients (40 stable (STA) and 40 BOS) identified 47 genes differentially expressed between STA and BOS recipients. An independent set of patients (13 STA, 11 BOS) was then used for external validation by qPCR. T-cell leukemia / lymphoma protein 1A (TCL1A) gene was identified and validated as a predictive marker of BOS more than 6 months before diagnosis with area under curve of 0.77. Accordingly, the invention relates to a method for predicting the risk of having the chronic lung allograft dysfunction (CLAD) and to a method for preventing the risk of having CLAD by administering immunosuppressive drugs.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products